查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1581226

核酸治療 CDMO 市場：按類型、服務、應用和最終用戶 - 2025-2030 年全球預測

Nucleic Acid Therapeutics CDMO Market by Type (DNA Therapeutics, RNA Therapeutics), Service (Analytical and Quality Control Services, Manufacturing Services, Process Development and Optimization), Application, End-user - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年核酸治療CDMO市場規模為96.9億美元，預計2024年將達到105.8億美元，複合年成長率為9.64%，預計到2030年將達到184.7億美元。

作為 360iResearch 的市場研究分析師，了解這個新興市場的範圍和細微差別對於關注核酸治療的合約研究、開發和受託製造廠商(CDMO) 領域至關重要。核酸療法，包括 mRNA、siRNA 和反義寡核苷酸，正在重新定義標靶治療，並為遺傳性疾病、癌症和病毒感染的治療提供了巨大潛力。這些療法的需求和應用突顯出它們直接針對遺傳條件的能力，提供了傳統治療方法無法實現的精確治療選擇。最終用途主要是生物技術和製藥公司，專門從事個人化醫療並擴大其開發平臺以納入這些新穎的治療方法。市場成長是由基因序列測定技術進步、慢性病盛行率上升以及個人化醫療趨勢不斷成長所推動的。此外，公共和私人投資正在加速這些突破性治療方法的開發。然而，仍有可能阻礙市場擴張的挑戰，例如高製造成本、擴充性問題、嚴格的法規環境和複雜的製造流程。機會在於發展夥伴關係關係，促進經濟高效的製造技術、增強的交付機制和技術共用的創新，以克服當前的限制。 CDMO 可以透過投資先進的技術平台（例如整合數位解決方案和自動化）來利用需求激增的機會，從而提高擴充性、法規遵循和上市速度。技術創新的關鍵領域包括脂質奈米顆粒等遞送系統的改進以及穩定製劑技術的發展，以確保將核酸有效負載安全地遞送至目標細胞。適應市場的性質需要靈活的方法和擴大的產品組合，包括從開發到商業生產的綜合服務。透過了解這些市場動態和潛在機會，公司可以更好地推進核酸療法，解決未滿足的醫療需求，並推動這一創新領域的強勁成長。

主要市場統計
基準年[2023] 96.9億美元
預測年份 [2024] 105.8億美元
預測年份 [2030] 184.7億美元
複合年成長率（%） 9.64%

市場動態：快速發展的核酸治療 CDMO 市場揭示的關鍵市場洞察

核酸療法 CDMO 市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球遺傳病患疾病率不斷上升
    • 增加經費和投入支持核酸研究
  • 市場限制因素
    • 核酸療法的製造成本高
  • 市場機會
    • 增加對核酸療法的監管核准
    • 個人化醫療的擴展帶來巨大潛力
  • 市場挑戰
    • 核酸療法擴充性的限制

波特五力：引領核酸治療 CDMO 市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解核酸治療 CDMO 市場的外部影響

外部宏觀環境因素在塑造核酸治療 CDMO 市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解核酸治療 CDMO 市場的競爭狀況

對核酸治療 CDMO 市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣核酸治療 CDMO 市場供應商的績效評估

FPNV定位矩陣是評估核酸治療CDMO市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃核酸治療 CDMO 市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對核酸治療 CDMO 市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：全面分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、核准核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地遺傳性疾病的發生率正在增加
      • 增加資金和投資支持核酸研究
    • 抑制因素
      • 核酸療法生產成本高
    • 機會
      • 核酸療法的監管核准增加
      • 個人化醫療的擴展帶來巨大潛力
    • 任務
      • 核酸治療的擴充性有限
  • 市場區隔分析
    • 類型：隨著感染疾病傳播的增加，mRNA療法持續取得進展
    • 應用：癌症發生率的增加增加了對創新和有效的癌症治療的需求。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 核酸治療 CDMO 市場：依類型

  • DNA療法
  • RNA療法

第7章核酸治療 CDMO 市場：依服務分類

  • 分析和品管服務
  • 製造服務
  • 製程開發與最佳化

第8章核酸治療藥物CDMO市場：依應用分類

  • 遺傳疾病
  • 感染疾病
  • 腫瘤學

第 9 章 核酸治療 CDMO 市場：依最終使用者分類

  • 生技公司
  • 政府及學術研究機構
  • 製藥公司

第10章 北美及南美核酸治療CDMO市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章 亞太地區核酸治療CDMO市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東、非洲核酸治療藥物CDMO市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • FUJIFILM Toyama Chemical 與 Synprogen 合作加強 mRNA 治療藥物的生產
    • Exothera 在北美推出先進的 RNA 治療平台“Ntensify”，簡化核酸藥物開發
  • 戰略分析和建議

公司名單

  • AGC Biologics Inc.
  • Agilent Technologies, Inc.
  • Ajinomoto Bio-Pharma Services
  • Almac Group Ltd.
  • Biomay AG
  • BioSpring GmbH
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • CordenPharma International GmbH
  • Creative Biogene
  • Danaher Corporation
  • Eurofins Scientific SE
  • Evonik Industries AG
  • GenScript Biotech Corporation
  • Lonza Group Ltd.
  • Polypeptide Group AG
  • Rentschler Biopharma SE
  • Sanofi SA
  • The Scripps Research Institute
  • Univercells Group
  • WuXi AppTec Co., Ltd.
Product Code: MRR-CA7E340319CD

The Nucleic Acid Therapeutics CDMO Market was valued at USD 9.69 billion in 2023, expected to reach USD 10.58 billion in 2024, and is projected to grow at a CAGR of 9.64%, to USD 18.47 billion by 2030.

As a Market Research Analyst at 360iResearch focusing on the Nucleic Acid Therapeutics Contract Development and Manufacturing Organization (CDMO) sector, it's essential to understand the scope and nuances of this evolving industry. Nucleic acid therapeutics, including mRNA, siRNA, and antisense oligonucleotides, are reshaping targeted therapies, offering immense promise in treating genetic disorders, cancers, and viral infections. The necessity and application of these therapeutics are underscored by their ability to target genetic conditions directly, providing precision treatment options that traditional therapies may not achieve. End-use is primarily in biotechnology and pharmaceutical companies dedicated to personalized medicine, expanding their R&D pipelines to include these novel modalities. Market growth is driven by technological advancements in genetic sequencing, increasing prevalence of chronic diseases, and a rising trend towards personalized medicine. Moreover, public and private investments are accelerating the development of these groundbreaking therapies. However, challenges persist, such as high production costs, scalability issues, stringent regulatory environments, and complex manufacturing processes that may hinder market expansion. Opportunities lie in innovating cost-effective manufacturing techniques, enhancing delivery mechanisms, and developing partnerships that facilitate technology sharing to overcome current limitations. CDMOs can capitalize on the burgeoning demand by investing in advanced technology platforms that enhance scalability, regulatory compliance, and speed to market, such as integrated digital solutions and automation. Critical areas of innovation include improving delivery systems, such as lipid nanoparticles, and evolving stable formulation technologies that ensure the safe delivery of nucleic acid payloads to targeted cells. Adapting to the market's nature requires an agile approach, expanding portfolios to include comprehensive services spanning from development to commercial manufacturing. By understanding these market dynamics and potential opportunities, businesses can better position themselves to advance nucleic acid therapeutics, addressing unmet medical needs and driving robust growth within this innovative sector.

KEY MARKET STATISTICS
Base Year [2023] USD 9.69 billion
Estimated Year [2024] USD 10.58 billion
Forecast Year [2030] USD 18.47 billion
CAGR (%) 9.64%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Nucleic Acid Therapeutics CDMO Market

The Nucleic Acid Therapeutics CDMO Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of genetic disorders worldwide
    • Increasing funding and investments support nucleic acid research
  • Market Restraints
    • High production costs of nucleic acid therapies
  • Market Opportunities
    • Rising regulatory approvals for nucleic acid therapies
    • High potential with the expansion of personalized medicine
  • Market Challenges
    • Limited scalability of nucleic acid therapies

Porter's Five Forces: A Strategic Tool for Navigating the Nucleic Acid Therapeutics CDMO Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Nucleic Acid Therapeutics CDMO Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Nucleic Acid Therapeutics CDMO Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Nucleic Acid Therapeutics CDMO Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Nucleic Acid Therapeutics CDMO Market

A detailed market share analysis in the Nucleic Acid Therapeutics CDMO Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Nucleic Acid Therapeutics CDMO Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Nucleic Acid Therapeutics CDMO Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Nucleic Acid Therapeutics CDMO Market

A strategic analysis of the Nucleic Acid Therapeutics CDMO Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Nucleic Acid Therapeutics CDMO Market, highlighting leading vendors and their innovative profiles. These include AGC Biologics Inc., Agilent Technologies, Inc., Ajinomoto Bio-Pharma Services, Almac Group Ltd., Biomay AG, BioSpring GmbH, Catalent, Inc., Charles River Laboratories International, Inc., CordenPharma International GmbH, Creative Biogene, Danaher Corporation, Eurofins Scientific SE, Evonik Industries AG, GenScript Biotech Corporation, Lonza Group Ltd., Polypeptide Group AG, Rentschler Biopharma SE, Sanofi SA, The Scripps Research Institute, Univercells Group, and WuXi AppTec Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Nucleic Acid Therapeutics CDMO Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across DNA Therapeutics and RNA Therapeutics.
  • Based on Service, market is studied across Analytical and Quality Control Services, Manufacturing Services, and Process Development and Optimization.
  • Based on Application, market is studied across Genetic Disorders, Infectious Diseases, and Oncology.
  • Based on End-user, market is studied across Biotech Companies, Government & Academic Research Institutes, and Pharmaceutical Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of genetic disorders worldwide
      • 5.1.1.2. Increasing funding and investments support nucleic acid research
    • 5.1.2. Restraints
      • 5.1.2.1. High production costs of nucleic acid therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising regulatory approvals for nucleic acid therapies
      • 5.1.3.2. High potential with the expansion of personalized medicine
    • 5.1.4. Challenges
      • 5.1.4.1. Limited scalability of nucleic acid therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Ongoing advancements in mRNA therapeutics with rising prevalence of infectious diseases
    • 5.2.2. Application: Rising incidence of cancer push the need for innovative and effective cancer treatments
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Nucleic Acid Therapeutics CDMO Market, by Type

  • 6.1. Introduction
  • 6.2. DNA Therapeutics
  • 6.3. RNA Therapeutics

7. Nucleic Acid Therapeutics CDMO Market, by Service

  • 7.1. Introduction
  • 7.2. Analytical and Quality Control Services
  • 7.3. Manufacturing Services
  • 7.4. Process Development and Optimization

8. Nucleic Acid Therapeutics CDMO Market, by Application

  • 8.1. Introduction
  • 8.2. Genetic Disorders
  • 8.3. Infectious Diseases
  • 8.4. Oncology

9. Nucleic Acid Therapeutics CDMO Market, by End-user

  • 9.1. Introduction
  • 9.2. Biotech Companies
  • 9.3. Government & Academic Research Institutes
  • 9.4. Pharmaceutical Companies

10. Americas Nucleic Acid Therapeutics CDMO Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Nucleic Acid Therapeutics CDMO Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Nucleic Acid Therapeutics CDMO Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FUJIFILM Toyama Chemical and Synplogen Forge Alliance to Enhance mRNA Therapeutics Production
    • 13.3.2. Exothera Launches Advanced RNA Therapeutics Platform 'Ntensify' in North America, Streamlining Nucleic Acid Drug Development
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AGC Biologics Inc.
  • 2. Agilent Technologies, Inc.
  • 3. Ajinomoto Bio-Pharma Services
  • 4. Almac Group Ltd.
  • 5. Biomay AG
  • 6. BioSpring GmbH
  • 7. Catalent, Inc.
  • 8. Charles River Laboratories International, Inc.
  • 9. CordenPharma International GmbH
  • 10. Creative Biogene
  • 11. Danaher Corporation
  • 12. Eurofins Scientific SE
  • 13. Evonik Industries AG
  • 14. GenScript Biotech Corporation
  • 15. Lonza Group Ltd.
  • 16. Polypeptide Group AG
  • 17. Rentschler Biopharma SE
  • 18. Sanofi SA
  • 19. The Scripps Research Institute
  • 20. Univercells Group
  • 21. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. NUCLEIC ACID THERAPEUTICS CDMO MARKET RESEARCH PROCESS
  • FIGURE 2. NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. NUCLEIC ACID THERAPEUTICS CDMO MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. NUCLEIC ACID THERAPEUTICS CDMO MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NUCLEIC ACID THERAPEUTICS CDMO MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NUCLEIC ACID THERAPEUTICS CDMO MARKET DYNAMICS
  • TABLE 7. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY DNA THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RNA THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ANALYTICAL AND QUALITY CONTROL SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT AND OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GOVERNMENT & ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. NUCLEIC ACID THERAPEUTICS CDMO MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. NUCLEIC ACID THERAPEUTICS CDMO MARKET, FPNV POSITIONING MATRIX, 2023